<SEC-DOCUMENT>0001558370-21-000389.txt : 20210126
<SEC-HEADER>0001558370-21-000389.hdr.sgml : 20210126
<ACCEPTANCE-DATETIME>20210126101404
ACCESSION NUMBER:		0001558370-21-000389
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210126
FILED AS OF DATE:		20210126
DATE AS OF CHANGE:		20210126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38976
		FILM NUMBER:		21551993

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tmb-20210126x6k.htm
<DESCRIPTION>6-K
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 1/26/2021 03:13:57 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Washington,&#160;D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">FORM&#160;6-K</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE&#160;13a-16 OR&#160;15d-16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">FOR THE&#160;MONTH OF JANUARY 2021</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;white-space:pre-wrap;">COMMISSION FILE NUMBER 001-38976  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">Genmab A/S<br></b><font style="background-color:#ffffff;color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">(Exact name of Registrant as specified in its charter)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Kalvebod Brygge 43</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">1560 Copenhagen V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Denmark</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">+45 70 20 27 28<br></b><font style="background-color:#ffffff;color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">(Address of principal executive offices)</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or&#160;Form&#160;40-F.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Form&#160;20-F&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      Form&#160;40-F&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Yes&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      No&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Yes&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      No&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="background-color:#ffffff;">This report on Form&#160;6-K&#160;shall be deemed to be&#160;</font>incorporated by reference<font style="background-color:#ffffff;">&#160;in Genmab A/S&#8217;s registration statements on&#160;</font><font style="background-color:#ffffff;">Form&#160;S-8</font><font style="background-color:#ffffff;">&#160;(File&#160;No.&#160;333-232693)&#160;and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">SIGNATURE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">nthony</p></div></div></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GENMAB A/S</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">BY:</font></p></td><td style="vertical-align:bottom;width:45.3%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ Anthony Pagano</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Name: Anthony Pagano</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Title: Executive Vice President &amp; Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">DATE: January 26, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">EXHIBIT&#160;INDEX</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.1127167%;width:102.22%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">O</font></p></div></div></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit</u></p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Description of Exhibit</u></p></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Company Announcement Dated January 26, 2021: Genmab Announces 2020 Net Sales of DARZALEX&#174; (daratumumab</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20210126xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 1/26/2021 03:13:54 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><img src="tmb-20210126xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;">Genmab Announces 2020 Net Sales of DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9.75pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;"> (daratumumab) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Company Announcement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Net sales of DARZALEX</b><sup style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:bold;text-align:left;vertical-align:top;">&#174;</sup><b style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"> in 2020 totaled USD 4,190 million</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. </b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Copenhagen, Denmark; January 26, 2021 &#8211; Genmab A/S (Nasdaq: GMAB) </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">announced today that worldwide net trade sales of DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-variant:small-caps;font-weight:bold;vertical-align:top;">&#174; </sup><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">(daratumumab), including sales of the subcutaneous formulation (sold under the tradename DARZALEX </b><font style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;">FASPRO</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-variant:small-caps;font-weight:bold;vertical-align:top;white-space:pre-wrap;">&#174;  </sup><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">in the U.S.</b><b style="font-family:'Arial','Helvetica','sans-serif';font-variant:small-caps;font-weight:bold;">)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">, as reported by Johnson &amp; Johnson were USD 4,190 million in 2020. </b><font style="font-family:'Arial','Helvetica','sans-serif';">Net trade sales were USD 2,232 million in the U.S. and USD 1,958 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX and DARZALEX </font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">FASPRO</i><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"> </b><font style="font-family:'Arial','Helvetica','sans-serif';">under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize daratumumab. As previously announced, Janssen is reducing its royalty payments to Genmab by what it claims to be Genmab&#8217;s share of Janssen&#8217;s royalty payments to Halozyme, cf. company announcement No. 39 of September 22, 2020.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> </font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">(daratumumab)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">DARZALEX</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> (daratumumab) has become a backbone therapy in the treatment of multiple myeloma. DARZALEX intravenous infusion is indicated for the treatment of adult patients in the United States: in combination with carfilzomib and dexamethasone for the treatment of  patients with relapsed/refractory multiple myeloma who have received one to three previous lines of therapy; in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">1 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">DARZALEX is indicated for the treatment of adult patients in Europe via intravenous infusion or subcutaneous administration: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">2</sup><font style="font-family:'Arial','Helvetica','sans-serif';">. Daratumumab is the first subcutaneous CD38 antibody approved in Europe for the treatment of multiple myeloma. The option to split the first infusion of DARZALEX over two consecutive days has been approved in both Europe and the U.S. </font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 04</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 1/3</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">21560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com </p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">LEI Code 529900MTJPDPE4MHJ122</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><img src="tmb-20210126xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;">Genmab Announces 2020 Net Sales of DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9.75pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;"> (daratumumab) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;">In Japan, DARZALEX intravenous infusion is approved for the treatment of adult patients: in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of relapsed or refractory multiple myeloma.  DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United States, Europe and Japan. For more information, visit www.DARZALEX.com.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a name="_Hlk39238089"></a><font style="font-family:'Arial','Helvetica','sans-serif';">DARZALEX</font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> FASPRO</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, is approved in the United States for the treatment of adult patients with newly diagnosed light-chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide, and dexamethasone. It is also approved in the U.S. for the treatment of adult patients with multiple myeloma: </font><a name="_Hlk61348865"></a><font style="font-family:'Arial','Helvetica','sans-serif';">in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for ASCT; </font><font style="font-family:'Arial','Helvetica','sans-serif';">in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for ASCT and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy; in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and as monotherapy, in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">3 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">DARZALEX </font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">FASPRO</i><font style="font-family:'Arial','Helvetica','sans-serif';"> is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme&#39;s ENHANZE</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> drug delivery technology. </font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">.</sup><font style="font-family:'Arial','Helvetica','sans-serif';">DARZALEX</font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> FASPRO</i><font style="font-family:'Arial','Helvetica','sans-serif';"> is the first subcutaneous CD38 antibody approved in the U.S. for the treatment of multiple myeloma and the first and only approved treatment for patients with AL amyloidosis in the U.S.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. Daratumumab triggers a person&#8217;s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">1,4,5,6,7</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a name="_Hlk39238148"></a><font style="font-family:'Arial','Helvetica','sans-serif';">Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and refractory and frontline multiple myeloma settings. Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases in which CD38 is expressed, such as amyloidosis and T-cell acute lymphocytic leukemia (ALL). Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA for certain indications of multiple myeloma, including as a monotherapy for heavily pretreated multiple myeloma and in combination with certain other therapies for second-line treatment of multiple myeloma.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a name="_Hlk34744061"></a><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About Genmab </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab&#8217;s proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 04</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 2/3</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">21560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com </p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">LEI Code 529900MTJPDPE4MHJ122</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><img src="tmb-20210126xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;">Genmab Announces 2020 Net Sales of DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9.75pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;"> (daratumumab) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Contact:</b></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">Marisol Peron, Senior Vice President, Global Investor Relations &amp; Communications</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">T: +1 609 524 0065; E: </font><font style="font-family:'Arial','Helvetica','sans-serif';">mmp@genmab.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For Investor Relations: </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Andrew Carlsen, Senior Director, Head of Investor Relations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">T: +45 3377 9558; E: </font><font style="font-family:'Arial','Helvetica','sans-serif';">acn@genmab.com</font><font style="font-family:'Arial','Helvetica','sans-serif';"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><font style="font-size:10pt;"><a name="_Hlk34743654"></a></font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">This Company Announcement contains forward looking statements. The words &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;anticipate&#8221;, &#8220;intend&#8221; and &#8220;plan&#8221; and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab&#8217;s most recent financial reports, which are available on www.genmab.com</i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> and the risk factors included in Genmab&#8217;s </i><font style="font-size:10pt;"><a name="_Hlk35592020"></a></font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">most recent Annual Report on Form 20-F </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">and other filings </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Genmab A/S and/or its subsidiaries own the following trademarks: Genmab</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; the Y-shaped Genmab logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; Genmab in combination with the Y-shaped Genmab logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; HuMax</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; DuoBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; DuoBody in combination with the DuoBody logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; HexaBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">;</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;"> </sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">HexaBody in combination with</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;"> </sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">the HexaBody logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; DuoHexaBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; HexElect</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; and UniBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">. DARZALEX</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> and DARZALEX FASPRO</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> are trademarks of Janssen Pharmaceutica NV. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">1</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> DARZALEX</font><font style="font-family:'Arial','Helvetica','sans-serif';"> Prescribing information, August 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761036s029lbl.pdf Last accessed August 2020</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">2</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> DARZALEX Summary of Product Characteristics, available at https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex Last accessed June 2020</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">3</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> </font><font style="font-size:10pt;"><a name="_Hlk39238185"></a></font><font style="font-family:'Arial','Helvetica','sans-serif';">DARZALEX </font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">FASPRO</i><font style="font-family:'Arial','Helvetica','sans-serif';"> Prescribing information, </font><font style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;">January 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761145s002lbl.pdf  Last accessed January 2021</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">4</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> </font><font style="font-family:'Arial','Helvetica','sans-serif';">De Weers, M et al. </font><font style="font-family:'Arial','Helvetica','sans-serif';">Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">5</sup><font style="font-family:'Arial','Helvetica','sans-serif';">Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">6 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;vertical-align:top;">7</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> Jansen, JH &#160;et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking.&#160;Blood. 2012; 120(21): abstract 2974</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 04</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 3/3</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">21560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com </p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">LEI Code 529900MTJPDPE4MHJ122</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tmb-20210126xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20210126xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !: 2\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#O/'/CNXT:
M\&G:>J^=C+R-V]A7*Z?\3=;M9PUR4N(NZD<_A6C\3?#=RNH_VO;QM)"XQ)M&
M=I]:\XR/6O1HTZ<H+0^9QF)Q-.N]6NQ](:#KEKK^FI>6QX/#*>JFM.O,?A4L
MUIIM_=SDQVFX$%N >.M7KSXHVD5RR6UFTT:G&\MC/Z5Q58J,VD>]A:LJM&,Y
M;L] HKG/#_C+3M>;RD)BN/\ GF_?Z>M='69T!13))$AC:21@J*,DGM7$:G\3
M+"UN&BM(&N=IP6S@?A0!W5<?XM\;1Z$_V2V02W9&3GHOUJ7P]XYLM>N#:F,P
M7!'RJ3D'\:\T\7PSV_BB]-R""[[E)[CVH NK\0-?6?S#,A7.=F#BO4/#.NIX
M@TE+H+L<?*Z^AKPF*-[B58H4,DC' 51DFO;?!>BR:)H213<32'>X]* .BHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ;)&DJ%)$5E/4,,@UAR>#= EG\Y]/CWYSP2!^5;U%-2:V(E3A/XE<QM
M;TT/X9N[*RC$9,1"*@Q7A#(T;LCJ593@@]J^D*Y;7/ NF:S,UP 8)VZM'W^M
M(M*QX[9SRVM]!/"Q61'!&/K7T+:.TEG [_>:-2?KBN/TKX=:=IMRMU<S/.8S
MN4-T'O6#K_Q#O1?O;Z6$C@B.W<1RV* .A^)-W/;>'E2$E5E?:Y'I7D/2O5_#
MVO6_C2PFTO5(E\X#)QT8>HJ$_"VS\_(O)O*S]W(S_*@#CO!5E/>>*+1H0VV%
MM[L.PKV._P!&L-44+>6R2XZ$CG\ZBT;0K'0[;R;.(+G[S'JWUK3H S+'P_I>
MFOOM;.-&]2,G]:TZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** *>JACI%V$^_Y38QZXKY[?
M(DDSUWG/YU]'D @@C(->;:_\.)YM0>YTV6-8Y#DHYQ@^U &#\/0Y\60[,X"G
M=],&O:*Y;PCX13P[&\LSB6ZD&&8= /05U- !11534M1M]*L);RY<+'&,G/>A
M*XFTE=ELD 9/2JKZG8QMM>[A5O0N*\AO?$7B#QMJ36FEAXK?/"IQ@>I-:$7P
MKU.2,-<:H1(1G <FNCV*C\;L>?\ 79U'^YA==SU6*:.9=T3JZ^JG-/KQJZ\-
M^+/"KBZL[B2XC4\[&+?F#7J7A^ZO;S1;>?4(A%<.N2HJ)TU%73NC>AB95).$
MXN+1IT445D=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,P52
MQZ 9I:.HQ0!RT'CS2;G6UTN'S3,6*$LF #74UX<4$'Q3"H, WF?S:O<:VK04
M;6.+!UYU>;GZ.P4445B=H4444 %%%% #9)%BC:1SA5&2:\;U_P ;ZI?:C*+2
MY>WMXV*J$[X[FO6]4C>72KJ-/OM$P'UQ7SW(I2:1&&&5R#^= 'J7@/Q;<:I(
M^GW[[YE&Y)#U85WM>,?#R&23Q7&Z [8U)8_@:]GH *\G^*^L.]W;Z5&QV*-[
M@=R>,5ZQ7@_C5S<>/9T)R!,J#Z9%=&&5YW['FYI-QH<JZNQZ=X!T6/2O#<#[
M )K@"1V[X/(%=55>PC$6GV\8Z+& /RJ&_P!8T_2V1;VZCA+C*[V S6,FY2;.
MRG&-*FELD7B 1@C-'3I6+_PENA?]!.W_ ._@J]8:K9:FK-97,<P7[Q1@<4G%
MK=%QJ0D[)HMNZQH7=@J@9))Z5P^L?$[3+"X:WM89+N13@E.E4OBAXBELK>+2
MK9RKSC,A!YV^E6? 7@^Q@T:&_O+=)KB<;AO&0HK:,(QASS.*KB*E2M[&CI;=
MD%E\5[*281WME-;@G[Y[?A7>V=[;W]LEQ;2K)$XR"#7.^)O"&F:II4WEVL<5
MPB%D>-0#FN,^%^K36NKSZ/*Y,1R5![,#CC]:;A"<7*&EB8UZU&LJ59W4MF>E
M:WK,&A:<][<*S1KUVBLW1/&>G:OID]\Q^S10L0WF&G^-U#>$;X$9^4?SKRKP
M5X8N/$QEB>Y:*QC(,J@_>/:BG3C*#DPQ&)JT\1&G!7NMCM;[XKZ9!,8[:UEG
M4'&\$ ?K6UX=\<Z9XAD\B/,-Q_SS<]:FM?!.@6MMY L(W&,%G )_.O)]=L4\
M.>.4CL2402JR#/0$XQ51A3J74=S.K6Q6':G4::;V/>:Y"^^(%C8Z\NE/;R^9
MO"L^< 9KJX7,D".>K*#7BGQ#C9O&[+%Q(X7!]\"LZ,%.5F=&.KSHTU.'<]'U
M_P =Z3H7[MG\^?\ YYQGI^-8VF?%73KNZ6&ZMI+=6. Y(('Y5-X?^'-C;Q"Y
MU7-W=R#+;CD#_&L+XD^&--TRPAO;* 0L6VLJ\ YK2$:3?(<]:IC(P]MHDNAZ
M+J6OZ=I5B+NYN46-AE<');Z"N*F^+EDL^(K"9HL_>W#FL+PCX4NO%:17>J7#
MM8P_+&F[D^WM7?W_ (+T)M(FA2QC0K&2KJH#9 ]:7+2@[2U92J8JO'GIVBOS
M+^@>(['Q%:>?9OR/O(>JUK,ZHI9V"J.I)P!7BWPUFDM/&+VBL=C*P8>N.E>P
MZA9)J%A-:2%@DJ[25."*SJTU"=NAT8/$2KT>9K5'.ZO\0=$TES'YIGE'58_\
M>E<^WQ<@#Y&ES^7Z[A6AHGPQTRP)EOB;J7.0#PH_"NFD\-Z-);F$Z=;A",<1
M@&KO1CI:YERXVIK=1\MRGX<\8:;XD#+;L8YE&3$_6NAKPNWA_P"$>^)$=O:L
M0B3@?@1G%>YJ<J#[5-:"BUR[,TP6(G5BU/=.QXC<D+\5 20 +H$D]OFKNM:^
M)6DZ5.UO$K74B\'8< &O.=?M);[Q_<6L#[))9]@;/3)KTW1_AYHVGVZBXA%S
M.1EWDY&?I6]3D2BY=CS\+[=RJ1I66N[,[3OBKI=U,L5S;RV^XXWL<C]*[N">
M*YA6:%U>-AD,IZUP'B_X?Z>^ERW>FQ>3/$-Q5>C#OQ5#X5:[*[RZ1,Y90-\6
M3T]:RE3A*'/#H=5+$5J=94:^M]F>I4445SGIA1110 5Q&N_#JUU.]:ZM9S;N
MYRZ@<&NWHH P_#?ABT\.VS+"3),_WY&ZFMRBB@ KP?QHA@\?3LPP#.K?AD5[
MQ7DOQ6TAXKVWU6-3L<;'([$<YKHPSM.W<\W-(.5#F71W/4K%Q+8P..C("/RK
M%\4^$;;Q0D(GF>)HCPR@&H? FMQ:MX<MTWCSX%$;KGGCC-=163O"6FYUQ4*]
M)7U3/)/$/PVM-&T.XOX[V61H@"%91@\XK0^$/_'C?_[R_P!:ZCQY_P B=??1
M?YBN7^$/_'C??[R_UKHYY2HMR/.5&G1QT(P5E;_,YGXER,WB^13T11C\A6K9
M>-_$MM90PPZ,&C1<*>>157XJ63V_B&&[Q\DR9S[C%>F^&+F&^\.V4\>ULQC/
ML:J4DJ<6U<RHTIRQ51*7*S@F\>^*64J=$X(QWK'\%V6HIXTM[F:SEC620EB1
MP,G->V;$_N+^5 10>% /TK+VR2:4=SL>!E*<93FW8PO&O_(I7W^Z/YUR'P?_
M ./74/JO]:Z_QK_R*5]_NC^=<A\'_P#CUU#ZK_6G'^#(FK_OT/1_J>G5XEX]
M_P"1\C_WD_\ 0J]MKQ+Q[_R/D?\ O)_Z%2PWQAFO\%>J/9[3_CTB_P!P5XYX
M[_Y*#']5_D*]CM/^/2+_ '!7CGCO_DH,?U7^0IX?XV&9_P "/JCV:+_4I_NB
MN#^*_P#R+L7_ %U'\Z[R+_4I_NBN#^*__(NQ?]=1_.LZ/\1'1C?]VEZ%SX8_
M\BE'_O'^9KK;S_CRG_ZYM_*N2^&/_(I1_P"\?YFNMO/^/*?_ *YM_*BK_$8\
M+_N\?0\7\!?\E ;_ +:5[9)(D4;2.P55&23VKQ/P%_R4!O\ MI7=_$R_ELO"
MS)$Q4SN(V(],'_"MJ\>:HD<. J*EAIS?1LS]8^)BK=FST2T-W+G&X]"?:JHU
M+XAW0\R.R\E3R 5'^%+\)],MVL[G4'16FW[ 3V'!_K7IE1.4:;Y4C6A"KB(*
MI.;5^B/ 86OIO'EN=2&+LSKY@Q[5[ZOW!]*\0F(E^*:$$$?:0/TKV\?='TIX
MA_#Z$Y8K>T7F>)S?\E67_KZ'_H5>VUXC.0/BJ"2 /M0Y/^]7MW6EB/L^A67;
MU/4KWP!T^Y!Z&)OY&O#_  5(UOXR8IGA)!Q7LVO7L=AH=W/(P $3#GU(Q7DG
MPTLFOO%#W# [$C;<?<U5'2G)LC'>]B*45N>VT445RGK!1110 4444 %%%% !
M5/5-,MM7L);.Z0-&XQ]#ZU<HH3MJ)I25F>*7WASQ#X,U%KK3#))!GAHP3D?[
M0%:%O\5M1@39>:>'D'!(.W],5ZTRAAA@"/0BL^YT^R+ FTMR?>,?X5TJJI_&
MKGESPDZ+_<S:7;<\GUCQKK7B>T>PMK!EAEP&"+N)_'%=A\-M"O\ 1M.N&OHO
M*,Q!52>1UZUV,%I;1*#';Q(?54 JQ4SJ^[R15D:X?"OVGMJDKLP/%OAN/Q)I
M+6YPLZ?-$_H:\NT_4_$G@6X>WDMG:#/*LI*GW!KW"HY8(9A^]BCD_P!Y0:5.
MK9<K5T5B<*IR]K!\LEU/+F^*M_/'Y=KI)\X]"#N_3%;W@EO$UU=W%[K&4MI1
ME8VX(/L.U=9#8V:$E;6!3ZB,"K8&!@4YSBE:,14*-1R4ZDV[?(P?&2/)X5O5
M12S%1@*,GK7)_"6WF@M;\30O'DKC>N,]:])90PPP!'H12)'''G8BKG^Z,5*G
M:#B:SH*5>-6^PZO&/'5I<R^.4>.WE=-R?,JDC[U>STQH8G;<T2,WJ5!-*E/D
M=PQ=!5X*+=M1EJ,6L0/]T5Y#XXM;F3QZDD=O*Z97YE4D=!7LE,:&)VW-&A;U
M*C-.G/DE<,505:"BW86+_5)_NBN&^*<,L_A^)8HGD;S1PHSWKNZ:\:2##HK#
MT(S4PERR3-*]/VE)P[G(?#6*2'PK&DL;(VX\,,'J:ZN[!-G.!R?+;^52*BH,
M(H4>@&*=2E*\KCI4^2FH=D>+^!;2YB\>&22WE1/WGS,I KTGQCH;:_H$UK'C
MSE^>//K6XL,2-N6)%;U"@&GUI.JW)2.>AA(PI2IMW3/#O#GB+4/!%W-;7EE(
M86/S(P(P?45T5U\1-2UI/L>AZ;()I/E\PY.W]*]$N[2VF4M+;Q.WJR FEM+2
MVA0&*WB0^JH!6DJD7[SCJ<]/#U8?NHU/=]/U/#-3TC5?"NMV=W<J99682!AR
M"WI7N=A</<Z=#<2Q&)W3<R'J*+V"&94\V)'PW&Y0<59 X K.I4YTKHWPN&5"
M<E%Z,\)U'2K_ %CQO=+:Q2QEYVV2[2 ,'KFMU/&OB7PT?L>J61F$?RK(1C(^
MO>O5Q#$K;EB0-ZA1FF3VT$ZGS88Y/]]0:MUE*R:T,%@G3O.$VFV>)ZKXCU_Q
MI(EE!;.(2?\ 5Q@X_$UZ9X*\,+X<TK;)@W4OS2L/Y5O6UK;P@&*"*,^JH!5B
2IJ5;KE2LC;#87EE[6<N:1__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
